Here on Campus we engage with the funding, R&D, service, and clinical communities to promote real-world utilization of the Sanger Institute’s technologies and resources.
The Institute has a proud heritage of achieving impact through rapid dissemination of its research findings, data and materials. In order that our cutting-edge research makes an impact on improving human health, further development, or translation, is often required. These translational approaches and activities vary on a case-by-case basis, and fall broadly into three types; spin-outs, licenses and collaborations.
Some of Sanger’s scaled technologies have become spin-out companies. Some research has been turned into licensed databases and resources to help disseminate knowledge and benefit the greater scientific community. It is also sometimes necessary to seek strategic commercial partnerships to help marry the formidable science base of the Institute with the capabilities of our commercial partners to add value or derisk technologies for mutual benefit. When deciding on the best application of Sanger’s research, we seek to achieve our charitable goal of creating public benefit. We interpret that goal as ensuring that we maximize the healthcare benefit of our science either directly ourselves or by facilitating others to do so, endeavouring to adopt actions that encourage and facilitate the availability of our results and products for the developing world.
Our scientists are encouraged to maximise the potential of their IP through partnerships with industry, and they are supported by mentors from industry. Alongside regular scientific activity, creating or working for a company is seen as a mark of success and offers the opportunity for academics to work with some of the best business minds in the world.
The Global Fight Against Malaria
Despite much progress that has been made to battle the disease, it remains a significant global healthcare challenge. It is found in more than 100 countries mainly in tropical regions of the world, disproportionately affecting poor and vulnerable populations. The ethos at Sanger demands that infectious diseases, such as malaria, currently afflicting the developing world receive equal attention and resource to the diseases of affluence such as cancer and type 2 diabetes. To effectively tackle malaria, we need better vaccines, medicines and disease surveillance. At Sanger, we are working to address all three of these areas.
Supporting the World's Cancer Research Community
In 2013, the advancing genomic revolution was increasing both the rate of cancer mutational data available and the need of the cancer research community for an accurate, centralised database to aggregate and interrogate relevant data. For over a decade, COSMIC filled the role of organising and hosting quality data but was running the risk of not keeping pace with the exponential growth of available data that needed curating. The danger was, that over time this important resource could lose its relevance and deprive the cancer research community of a key source of up-to-date information.
Advancing Healthcare through Genomics
Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica, has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service. In this case study, we share the story of this spinout from the Wellcome Sanger Institute, how it is advancing healthcare through genomics and the role of the Technology Translation Team, which made this possible.
Novel antibody therapeutics at Sanger’s first ever spin-out
The Wellcome Sanger Institute‘s first-ever spin-out, Kymab Ltd was acquired by Sanofi in 2021. Founded by the former Institute director and Sanger researcher, Allan Bradley, Kymab’s therapeutics are designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases. A great example of the power of innovation and technology translation. Want to know how this incredible science became a tool to fight diseases?
Partner with Sanger
To find out more about how we may be able to collaborate or to ask one of our business development team to give a talk on commercialisation of scientific research, please get in touch.Contact us